Introduction and Current Landscape of HER2 in NSCLC

Key Takeaways

• HER2 mutations involve genetic alterations, while HER2 expression refers to protein overexpression, both impacting NSCLC treatment strategies.
• Fam-trastuzumab deruxtecan-nxki and ado-trastuzumab emtansine are key HER2-directed therapies recommended by NCCN guidelines for HER2-positive NSCLC.
• These therapies have demonstrated efficacy and safety, potentially transforming treatment paradigms for HER2-positive NSCLC patients.
• Ongoing research and clinical trials are crucial for optimizing HER2-directed therapy use and exploring new treatment options in NSCLC.